News | September 05, 2007

Targeted Therapies Offer New Hope for Brain Cancer Patients

September 6, 2007 – According to a new report by Datamonitor, significant progress is being made with research into the disease and innovative new therapies may be able to improve survival of brain cancer patients.

The most aggressive and most common form of brain cancer is known as glioblastoma multiforme (GBM), accounting for over half of all brain tumors diagnosed each year. Datamonitor predicts that there will be around 26,000 new cases of GBM diagnosed in the seven major markets in 2007. In the US alone, around 14,000 people will die from brain cancer in 2007.

For GBM patients, standard treatment currently involves surgical removal of the tumor followed by radiotherapy and chemotherapy. The favored brand of chemotherapy for most physicians is Schering-Plough’s Temodar (temozolomide). While survival is low for most GBM patients treated in this way (on average, just over 14 months), Datamonitor found in its research that this mode of treatment was commonly used in all of the seven major markets.

In comparison to some other types of cancer, brain tumors are less prevalent. Therefore, from a drug developer’s point of view, targeting the disease may not be considered as commercially viable compared to the four major types of cancer - breast, prostate, lung and colorectal cancer.

However, there are several incentives for drug developers to focus on brain cancer. The poor survival prospects with currently available treatment options mean that there could be rapid uptake of a new brain cancer drug providing just a modest improvement in survival. There is also a significant opportunity in the market for a second-line therapy to be used if and when the disease relapses after standard treatment fails, according to Datamonitor oncology analyst Dr. Tom Gray.

Consequently, there has been a considerable amount of research and development activity in brain cancer, and there are several innovative drugs currently in the development pipeline. Many of these drugs are targeted therapies which, rather than indiscriminately destroying cells like traditional chemotherapy, are intended to specifically destroy or prevent the growth of cancer cells.

Some of the more promising targeted therapies in the pipeline for brain cancer include Genentech/Roche’s Avastin (bevacizumab) and AstraZeneca’s Recentin (cediranib) which are currently in Phase II clinical trials. These drugs both work by preventing the growth of new blood vessels from the tumor, therefore starving it of oxygen and nutrients and preventing it from growing, Dr. Gray says.

However, as these drugs have not yet entered Phase III trials, it is likely to be at least another two years before these drugs are available to brain cancer patients.

While there is generally a great deal of optimism amongst brain cancer experts surrounding targeted therapies, it appears unlikely that Temodar will be superseded in the near future as the number one drug therapy for brain cancer. Physicians interviewed by Datamonitor envisage targeted therapies being used alongside Temodar, rather than directly replacing it.

Advances in diagnostic methods mean that a more detailed picture of the nature of brain cancer is beginning to emerge. For example, it is now known that certain proteins are present in the tumor cells of some brain cancer patients, but not in others, due to the differing genetic characteristics of these patients. Consequently, it is likely that some patients will benefit more than others from particular treatments.

For more information: www.datamonitor.com

Related Content

MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat
Carestream, Clinical Collaboration Platform, Fox Valley Hematology & Oncology
News | Enterprise Imaging | April 20, 2016
Fox Valley Hematology & Oncology (Appleton, Wis.) implemented Carestream’s Vue for Clinical Collaboration Platform...
cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging
News | Oncology Related Products | March 31, 2016
In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy...
Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical

News | Oncology Related Products | March 15, 2016
Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical), concluding a...
BTG, LC Bead LUMI, radiopaque embolic bead, Philips Healthcare, Live Image Guidance, liver cancer
News | Interventional Radiology | February 09, 2016
BTG plc and Royal Philips announced a significant milestone in their collaboration with the treatment of the first...
Overlay Init